Skip to main content
SpringerLink
Log in

Herzfrequenzreduktion — ein wichtiger Mechanismus für eine günstige Beeinflussung der Prognose

  • Chapter
Book cover Betablocker — im Mittelpunkt der Forschung

  • 27 Accesses

Zusammenfassung

Die Herzfrequenz ist ein prognostischer Index des kardiovaskulären Risikos vor, während und nach einem koronaren Ereignis [1,2,3]. Nach einem akuten Myokardinfarkt beträgt das Risikoverhältnis fär Patienten mit einer Herzfrequenz äber 90 Schlägen pro Minute bezogen auf Patienten mit einer Herzfrequenz unter 60 Schlägen pro Minute 2,7, und das Risiko steigt bei über 110 Schlägen pro Minute deutlich an.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Kannel WB, Kannel C, Paffenbarger RS, Adrenne PH, Adrenne L (1987) Heart rate and cardiovascular mortality: The Framingham Study, Am Heart J 113: 1489–1494.

    Article  PubMed  CAS  Google Scholar 

  2. Hjalmarson Å, Gilpin E, Kjekshus J, Scheiman G, Nicod P, Henning H, Ross J (1990) Influence of heart rate on mortality after acute myocardial infarction. Am J Cardiol, March 1: 547–553.

    Article  Google Scholar 

  3. Dyer AR, Persky V, Stampler J et al. (1980) Heart rate as a prognostic factor for coronary heart disease and mortality: Findings in three Chicago epidemiologic studies. Am J Epidemiol 112: 736–749.

    PubMed  CAS  Google Scholar 

  4. Moser DK, Stevenso WG, Woo MA, Stevenson LW (1994) Timing of sudden death in patients with heart failure. J Am Coll Cardiol 24: 963–7.

    Article  PubMed  CAS  Google Scholar 

  5. ISIS-2 collaborative group (1992) Morning peak in the incidence of myocardial infarction: experience in the ISIS-2 trial. Eur Heart J 13: 594–598.

    Google Scholar 

  6. Sandvik L, Erikssen J, Ellestad M, Erikssen G, Thaulow E, Mundial R, Rodahl K (1995) Heart rate increase and maximal heart rate during exercise as predictors of cardiovascular mortality: a 16-year follow-up study of 1960 healthy men. Coron Art Dis 1995; 6: 667–679.

    Article  CAS  Google Scholar 

  7. Cripps TR (1991) Prognostic value of reduced heart rate varibility after myocardial infarction in clinical evaluation of a new analysis method. Br Heart J 65: 1449.

    Article  Google Scholar 

  8. Beere PA, Glasgow S, Zarins CK 1984 Retarding effect of lowered heart rate on coronary atherosclerosis. Science 226: 180–182.

    Article  PubMed  CAS  Google Scholar 

  9. Williams PT, Haskell WL, Vranizan KM et al. (1985) Associations of resting heart rate with concentrations of lipoprotein subfractions in sedentary men. Circulation 1985; 71: 441–449.

    Article  PubMed  CAS  Google Scholar 

  10. Brown BG, Zhao X-Q, Sacco DE et al. (1993) Lipid-lowering and plaque regression: new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 87: 1781–91.

    PubMed  CAS  Google Scholar 

  11. Bristow MR, Lowes BD 1994 Low dose inotropic therapy for ambulatory heart failure. Coronary Artery Dis 5: 112–8.

    Article  CAS  Google Scholar 

  12. Kjekshus J (1986) Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 57: 43f–49f.

    Article  PubMed  CAS  Google Scholar 

  13. Noda T, Arakawa M, Miwa H et al. (1996) Effects of heart rate on flow velocity of the left atrial appendage in patients with nonvalvular atrial fibrillation. Clin Cardiol 19: 295–300.

    Article  PubMed  CAS  Google Scholar 

  14. Kjekshus J, Schytte-Blix A, Eisner R, Hoi R, Amundsen E (1982) Myocardial blood flow and metabolism in the diving seal. Am J Physiol 242: 97–104.

    Google Scholar 

  15. Eisner R, Millard RW, Kjekshus JK, White F, Blix AS, Kemper S (1985) Coronary blood flow and myocardial segment dimensions during simulated dives in seals. Am J Physiol 249: 1119–1126.

    Google Scholar 

  16. Kjekshus JK, Blix AS, Grøttum P, Aasen AO (1981) Beneficial effects of vagal stimulation on the ischaemic myocardium during beta-receptor blockade. Scand J Clin Lab Invest; 41: 383–389.

    Article  PubMed  CAS  Google Scholar 

  17. Simonsen S, Ihlen J, Kjekshus JK (1983) Haemodynamic and metabolic effects of timolol (blocadren) on ischaemic myocardium. Acta Med Scand 213: 393–8.

    Article  PubMed  CAS  Google Scholar 

  18. Boudoulas H, Rittgers E, Lewis RP, Leier CV, Weissler A (1979) Changes in diastolic time with various pharmacologic agents. Circulation 60: 164–169.

    PubMed  CAS  Google Scholar 

  19. Domench RJ, La Prida JM de (1975) Mechanical effects of heart contraction on coronary flow. Cardiovasc Res 9: 509–514.

    Article  Google Scholar 

  20. Niemela MJ, Airakasinen KEJ, Huikuri H (1994) Effect of beta-blockade on heart rate variability in patients with coronary artery disease. J Am Coll Cardiol 6: 1370–1377.

    Article  Google Scholar 

  21. Mjøs OD, Kjekshus J, Lekven J (1974) Importance of free fatty acids as a determinant of myocardial oxygen consumption and myocardial ischemic injury during norepinephrine infusion in dogs. J Clin Invest 53: 1290–1299.

    Article  PubMed  Google Scholar 

  22. Sugiyama S, Hattori M, Miyazaki Y, Nagai S, Ozawa T (1985) Mechanism of antiarrhythmic action of beta-blocking agents. J Electrocardiology 18 (2): 169–174.

    Article  CAS  Google Scholar 

  23. International Collaborative Study Group (1984) Reduction in infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med; 310: 9–15.

    Article  Google Scholar 

  24. Shell WE, Sobel BE (1973) Deleterious effects of increased heart rate on infarct size in the conscious dog. Am J Cardiol 31: 474–79.

    Article  PubMed  CAS  Google Scholar 

  25. Sirnes PA, Overskeid K, Pedersen T et al. (1984) Evolution of infarct size during the early use of nifedipine in patients with acute myocardial infarction: The Norwegian Nifedipine Multicenter Trial. Circulation 70: 638–644.

    Article  PubMed  CAS  Google Scholar 

  26. The Danish Study Group on Verapamil in Myocardial Infarction (1990) Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish verapamil infarction trial II-DAVIT II). Am J Cardiol 66: 779–885.

    Article  Google Scholar 

  27. Kailasam MT, Parmer RJ, Cervenka JH et al. (1995) Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonist classes on autonomic function in human hypertension. Hypertension 26: 143–149.

    PubMed  CAS  Google Scholar 

  28. ISIS I (First International Study of Infarct Survival) Collaborative Group (1986) Randomised trial of intravenous atenolol among 16027 cases of suspected acute myocardial infarction: ISIS - I. Lancet 2: 57–66.

    Google Scholar 

  29. The MIAMI Trial Research Group (1985) Metoprolol in acute myocardial infarction (MIAMI): A randomised placebo-controlled international trial. Eur Heart J 6: 199–226.

    Google Scholar 

  30. Roberts R, Rogers WJ, Mueller HS et al. (1991) Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Circulation 2: 422–437.

    Google Scholar 

  31. Gundersen T, Grøttum P, Pedersen T, Kjekshus K (1986) Effect of timolol on mortality and reinfarction after myocardial infarction: prognostic importance of heart rate at rest. Am J Cardiol 58: 20–24.

    Article  PubMed  CAS  Google Scholar 

  32. Yusuf S, Lewis PR, Collins R, Sleight P (1985) Beta blockade during and after myocardial infarction. An overview of the randomized trials. Prog Cardiovasc Dis 27: 335–371.

    CAS  Google Scholar 

  33. Forfang K, Gullestad L (1995) Medical treatment of angina pectoris - Are the possibilities exploited well enough? Tidsskr Nor Laegeforen 115: 2264–7.

    PubMed  CAS  Google Scholar 

  34. Gullestad L, Kjekshus J (1992) Heart disease in diabetes mellitus. Tidsskr Nor Laegeforen 1992; 112: 1016–19.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. J. Kjekshus
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institut für Pharmakologie, Med. Universität zu Lübeck, Ratzeburger Allee 160, D-23538, Lübeck, Germany

    P. Dominiak

  2. Division of Cardiology, Sahlgrenska University Hospital, S-413345, Göteborg, Germany

    A. Hjalmarson

  3. Clinical Pharmacology Section, University of Birmingham, Edgbaston, Brimingham B15 2TH, Edgbaston, UK

    M. J. Kendall

  4. Innere Medizin III, Universität Heidelberg, Bergheimer Str. 58, D-69115, Heidelberg, Germany

    W. Kübler

  5. Astra Hässle AB, Clinical R&D, S-43183, Mölndal, Sweden

    G. Olsson

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Kjekshus, J. (1997). Herzfrequenzreduktion — ein wichtiger Mechanismus für eine günstige Beeinflussung der Prognose. In: Dominiak, P., Hjalmarson, A., Kendall, M.J., Kübler, W., Olsson, G. (eds) Betablocker — im Mittelpunkt der Forschung. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60716-5_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-60716-5_15

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-64522-8

  • Online ISBN: 978-3-642-60716-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation